ClinicalTrials.gg
RecruitingNCT07398495Updated Mar 30, 2026

Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia

An interventional study of Multimodal Exercise Program in Type 2 Diabetes Mellitus (T2DM) and Sarcopenia, sponsored by yueh chu wu. Recruiting at 1 site in Taiwan. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by yueh chu wu · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 278 studies in Diabetes Mellitus, Type 2 with a site in Taiwan — 36 open to participants now, 41 under way, 14 of them phase 3. Diabetes Mellitus, Type 2 · Taiwan.

Planned enrollment
176th of 245
128 · median 435
Started
2026
with 16 others
No phase
57 of 278
12 open now
Primary completion
2026-05
later than 11 of 40 live
Registered
260th of 278
by date

Among the 278 studies in Diabetes Mellitus, Type 2 with a site in Taiwan, this one is the 176th largest by planned enrollment of the 245 interventional ones that give a count, is one of 17 that started in 2026, is one of 57 with no phase, reaches primary completion later than 11 of the 40 other live ones, and was the 260th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

36 of the 278 studies in Diabetes Mellitus, Type 2 with a site in Taiwan are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 278 studies in Diabetes Mellitus, Type 2 with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to investigate the effects of a 12-week multimodal exercise intervention on middle-aged and older adults (aged 45\~85 years) with Type 2 Diabetes Mellitus (T2DM). The program combines supervised training, home-based sessions, and digital support to improve muscle function, physical performance, metabolic control, and quality of life.

Read the detailed description

Middle-aged and older adults with T2DM, particularly in Asian populations, face a heightened risk of sarcopenia. This condition leads to a decline in muscle mass and function, negatively impacting quality of life. Effective interventions are urgently needed to slow disease progression. This randomized controlled trial will recruit 128 adults. Participants will be randomly assigned to either a control group or an intervention group. The intervention involves a multimodal exercise program and educational materials, while the control group receives standard health education. Assessments will be conducted at baseline, week 12, and week 24 to evaluate physical function, sarcopenia risk, metabolic control, and quality of life.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Sarcopenia
04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with both Type 2 Diabetes Mellitus (T2DM) and sarcopenia.
  • Maintained on a stable regimen of oral hypoglycemic agents.
  • Aged 45 years or older.
  • Capable of communicating effectively in Mandarin or Taiwanese.
  • Willing to provide or have it obtained from a legally authorized representative.

Exclusion criteria

Exclusion Criteria:

    • Limited limb or joint function that prevents exercise (e.g., recent fractures or dislocations).

      • Communication barriers or severe emotional/psychological issues (e.g., uncontrolled depression or severe mental illness).
      • Severe cognitive impairment (e.g., dementia).
      • End-stage renal disease (ESRD).
      • Major comorbidities or complications, including active diabetic foot ulcers, amputation, recent myocardial infarction, severe autonomic neuropathy, or a history of stroke within the last 3 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Intervention Group (Multimodal Exercise)

    • Arm Description: Participants in this group will engage in a 12-week multimodal exercise program. The program includes supervised training sessions, home-based exercises, and digital support. They will also receive a "Diabetes and Muscle Health Handbook" to guide their training.

    Behavioral: Multimodal Exercise Program

  • No intervention
    Control Group (Standard Care)

    Participants in this group will serve as the control. They will receive a "Nutrition and Muscle Health Education Sheet" at the beginning of the study. They will not participate in the multimodal exercise program and will continue with their routine health management based on existing medical advice.

Interventions

  • BehavioralMultimodal Exercise Program

    Participants will engage in a 12-week multimodal exercise program comprising supervised training sessions, home-based exercises, and digital support. To facilitate adherence and proper technique, participants will also receive a "Diabetes and Muscle Health Handbook" as a training guide.

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. Physical Function (5TSTS)

    The Five-Times Sit-to-Stand Test (5TSTS) assesses lower limb muscle power. Participants are asked to stand up and sit down five times as quickly as possible with arms folded. The time to completion is recorded in seconds and analyzed as a continuous variable. According to the 2019 Asian Working Group for Sarcopenia (AWGS) consensus, a completion time of ≥ 12 seconds is considered abnormal and indicates low physical performance.

    Time frame: Change from Baseline at Week 12 and Week 24

  2. Handgrip Strength (HGS)

    Handgrip strength (HGS) is assessed using a digital dynamometer (e.g., Jamar or an equivalent device). During the assessment, participants stand with their testing arm fully extended. Two consecutive trials are performed for each hand, and the maximum grip strength value (in kilograms) is selected for data analysis. Based on the 2019 Asian Working Group for Sarcopenia (AWGS) consensus, low muscle strength is defined as \< 28 kg for men and \< 18 kg for women

    Time frame: Change from Baseline at Week 12 and Week 24

  3. Skeletal Muscle Mass Index (SMI)

    Determined by bioelectrical impedance analysis (BIA). Appendicular skeletal muscle mass (ASM, kg) is calculated as the sum of lean mass from both arms and legs. SMI is expressed as ASM divided by height squared (kg/m²). Low muscle mass is defined according to AWGS 2019 cut-off values (\<7.0 kg/m² for men and \<5.7 kg/m² for women).

    Time frame: Change from Baseline at Week 12 and Week 24

  4. Sarcopenia Risk: Assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire combined with calf circumference measurement (SARC-CalF).

    Assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire combined with calf circumference measurement (SARC-CalF). The SARC-F assesses 5 items scored 0-10. A calf circumference ≤34 cm (men) or ≤33 cm (women) adds 10 points. Total SARC-CalF scores range from 0 to 20. Higher scores indicate a higher risk of sarcopenia (a worse outcome). A total SARC-CalF score ≥11 indicates a high risk.

    Time frame: Change from Baseline at Week 12 and Week 24

Secondary outcomes

  1. Glycated Hemoglobin (HbA1c)

    Metabolic control is evaluated by HbA1c levels. Venous blood samples are collected after an overnight fast and analyzed using standardized high-performance liquid chromatography (HPLC). Values are reported as percentages. According to the American Diabetes Association (ADA) guidelines, the target HbA1c level for patients with type 2 diabetes mellitus (T2DM) is \< 7.0%.

    Time frame: Change from Baseline at Week 12 and Week 24

  2. Quality of Life (SF-12)

    Assessed using the 12-Item Short Form Health Survey (SF-12). The survey covers eight domains summarized into two composite scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Change from Baseline at Week 12 and Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wu YC, Liao LN, Lai YF, Huang HE, Liao WC, Huang CN. Sustained and attenuated effects of transitioning from supervised to self-managed resistance training in older adults with type 2 diabetes and sarcopenia: a randomized controlled trial. Acta Diabetol. 2026 Jul 13. doi: 10.1007/s00592-026-02736-y. Online ahead of print. PubMed 42440096 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2026, 2 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 2 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 10, 2026
StartActual
Feb 23, 2026
Primary completionEst.
May 15, 2026
CompletionEst.
Aug 15, 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07398495
Lead sponsor
yueh chu wu
Responsible party
yueh chu wu (Principal Investigator, Chung Shan Medical University) — Sponsor-investigator
First posted
Feb 10, 2026
Start date
Feb 23, 2026
Primary completion
May 15, 2026 (estimated)
Completion
Aug 15, 2026 (estimated)
Last update
Mar 30, 2026

Study contacts

yueh chu wu WU YUEH CHU
Contact
yueh.chu46240@gmail.com
886-952680613

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion